LEADER 04930nam 2201165z- 450 001 9910576878903321 005 20220621 035 $a(CKB)5720000000008386 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/84555 035 $a(oapen)doab84555 035 $a(EXLCZ)995720000000008386 100 $a20202206d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aAdvance in the Treatment of Pediatric Leukemia 210 $aBasel$cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 online resource (300 p.) 311 08$a3-0365-4167-5 311 08$a3-0365-4168-3 330 $aThe book gives an overview on the progress that has been made in the treatment of acute lymphoblastic leukemia (ALL), of acute and chronic myeloid leukemia (AML, CML) and of juvenile myelomonocytic leukemia (JMML). Leukemia is the most common malignant disease in children, and 80% of patients are diagnosed with ALL and 15-20% with AML, whereas CML and JMML are rather rare. Although ALL was considered an incurable disease until the early 1960s, with the availability of cytotoxic drugs and the start of clinical multicenter studies, ALL has become an almost curable disease with a survival rate exceeding 90 % in high-income countries. These impressive results have mainly been achieved by a deeper understanding of the genomic landscape of the disease and the introduction of risk stratifications based on genetic features and response to chemotherapy as determined by the presence or absence of minimal residual disease (MRD). Immunotherapies including bispecific T-cell Engagers (BiTEs), Chimeric Antigen Receptor (CAR) T cells, monoclonal antibodies and improvements in the outcome of allogeneic stem cell transplantation (HSCT) have shown impressive results in chemorefractory or relapsed patients, and it is anticipated that the cure rate can be further increased. For countries with less resources, therapies have to be adapted to increase survival as well. This book also updates on the progress made in the treatment of AML. As in ALL, risk classification based on genetic factors and response to chemotherapy is most important for therapy guidance. The book also provides updates and guidance for the treatment of CML and JMML. 606 $aChemistry$2bicssc 606 $aResearch & information: general$2bicssc 610 $a5-azacitidine 610 $aABCC4 610 $aacute lymphoblastic leukemia 610 $aacute myeloid leukemia 610 $aacute pancreatitis 610 $aADC 610 $aadvances 610 $aALL 610 $aallogeneic stem cell transplantation 610 $aalternative donors 610 $aAML 610 $aantibody 610 $aantibody-drug conjugate 610 $aB-ALL 610 $aBCL11B 610 $aBCP-ALL 610 $abispecific T-cell engager (BiTE) 610 $aCD19 610 $aCFTR 610 $achildhood acute lymphoblastic leukemia 610 $achildren 610 $achronic myeloid leukemia 610 $aCML 610 $aconditioning regimen 610 $aCOVID-19 610 $adiagnosis 610 $aDUX4 610 $aevolution of CAR T cells 610 $aFc-engineering 610 $aFDA-approved CAR products 610 $afuture directions of CAR T cell therapy 610 $agenome 610 $ahematopoietic stem cell transplantation 610 $aIKZF1 610 $aimmunizations 610 $aimmunotherapy 610 $ajuvenile myelomonocytic leukemia 610 $aL-asparaginase 610 $aleukemia 610 $alimitations and complications of CAR T cell therapy 610 $alow-risk ALL 610 $alymphoblastic leukemia 610 $aminimal residual disease 610 $amyelodysplastic/myeloproliferative disorders 610 $an/a 610 $aNOTCH1 610 $aNUTM1 610 $aother extramedullary relapse 610 $aPAX5 610 $apediatric 610 $apediatric leukemia 610 $aPh-like 610 $apolymorphism 610 $aprognosis 610 $aRAS signaling 610 $arisk-stratified treatment 610 $aSNV 610 $aT-ALL 610 $atargeted therapy 610 $aTcR versus CAR 610 $aTRAIL 610 $atranscriptome 610 $atreatment 610 $atreatment related toxicity 610 $atyrosine kinase inhibitor 610 $axenograft 610 $aZNF384 615 7$aChemistry 615 7$aResearch & information: general 700 $aHandgretinger$b Rupert$4edt$01326310 702 $aHandgretinger$b Rupert$4oth 906 $aBOOK 912 $a9910576878903321 996 $aAdvance in the Treatment of Pediatric Leukemia$93037296 997 $aUNINA